Atreca to Highlight ATRC-101 Preclinical Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 05 2019 - 8:00AM
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company
focused on developing novel therapeutics based on a deep
understanding of the human immune response, today announced that it
will present a poster describing preclinical evaluations of
ATRC-101 at the upcoming 34th Annual Meeting of the Society for
Immunotherapy of Cancer (SITC 2019), to be held from November 6-10
in National Harbor, MD. ATRC-101 is a novel, first-in-class
therapeutic candidate that targets a tumor-associated
ribonucleoprotein complex, derived from a human antibody discovered
by Atreca’s proprietary Immune Repertoire Capture® (IRC™) platform.
The poster will describe the characterization and target of
ATRC-101 and will include preclinical data highlighting ATRC-101’s
robust anti-tumor activity as monotherapy and favorable safety
profile. Atreca remains on track to file an Investigational New
Drug (IND) application for ATRC-101 during the fourth quarter of
2019, with plans to commence a Phase 1b study in multiple solid
tumor types in early 2020.
Details of the presentation are as follows:
Presentation Title: “ATRC-101: A First-in-Class
Engineered Fully Human Monoclonal Antibody that Targets a
Tumor-Restricted Ribonucleoprotein Complex”Date:
Saturday, November 9, 2019Time: 7:00AM – 8:30 PM
PST Location: Gaylord National Hotel &
Convention Center, National Harbor, MDCategory:
Novel Single-Agent ImmunotherapiesPoster/Abstract
Number: P778Authors: Norman M. Greenberg,
PhD, et al.
About ATRC-101ATRC-101 is a monoclonal antibody
derived from an antibody identified using Atreca’s discovery
platform. ATRC-101 functions through a novel mechanism of action,
referred to by Atreca as Driver Antigen Engagement. This mechanism
involves systemic delivery of an agent that causes extensive
remodeling of the tumor microenvironment and the destruction of
tumor cells via both the innate and adaptive immune systems. Atreca
has identified the target of ATRC-101 as a ribonucleoprotein (RNP)
complex. ATRC-101 has demonstrated robust anti-tumor activity as a
single agent in multiple preclinical syngeneic tumor models,
including one model in which PD-1 checkpoint inhibitors typically
display limited activity. ATRC-101 has also demonstrated
preclinical activity in combination with other immunotherapeutics
(including PD-1 checkpoint inhibitors). Further, ATRC-101 has been
shown to react in vitro with a majority of human ovarian, non-small
cell lung, colorectal and breast cancer samples from multiple
patients.
About Atreca, Inc. Atreca is a
biopharmaceutical company utilizing its differentiated platform to
discover and develop novel antibody-based immunotherapeutics to
treat a range of solid tumor types. Atreca’s discovery platform
relies on the human immune system to discover unique
antibody-target pairs from patients experiencing an active immune
response against their tumors. These unique antibody-target pairs
represent a potentially novel and previously unexplored landscape
of immuno-oncology targets and provide the basis for novel clinical
therapeutic candidates such as ATRC-101, the company’s lead
clinical candidate. The company expects to file an Investigational
New Drug application for ATRC-101 in the fourth quarter of 2019 and
to commence a Phase 1b study in multiple solid tumor types in early
2020. For more information on Atreca, please visit
www.atreca.com.
Forward-Looking Statements This release
contains forward-looking statements regarding our strategy and
future plans, including statements regarding the development of
ATRC-101 and our clinical and regulatory plans, and the timing
thereof. These forward-looking statements include, but are not
limited to, statements about our plans, objectives, representations
and contentions and are not historical facts and typically are
identified by use of terms such as “will”, “expect,” “believe,”
“potential,” “continue,” and similar words, although some
forward-looking statements are expressed differently. Our actual
results may differ materially from those indicated in these
forward-looking statements due to risks and uncertainties related
to the initiation, timing, progress and results of our research and
development programs, preclinical studies, any clinical trials and
Investigational New Drug application and other regulatory
submissions, and other matters that are described in our
prospectus, dated June 19, 2019, as filed with the Securities and
Exchange Commission (SEC) pursuant to Rule 424(b) under the
Securities Act of 1933, as amended, and in our Quarterly Report on
Form 10-Q for the quarter ended June 30, 2019, which are available
on the SEC’s website at www.sec.gov, including the risk factors set
forth therein. Investors are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date of this release, and we undertake no obligation to update any
forward-looking statement in this press release, except as required
by law.
ContactsAtreca, Inc. Herb Cross Chief Financial
Officer info@atreca.com Investors: Alex Gray, 650-779-9251, ext.
251 agray@atreca.com
Media:Sheryl Seapy, 213-262-9390sseapy@w2ogroup.com
Source: Atreca, Inc.
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024